financetom
Business
financetom
/
Business
/
Barrick Gold Provides Update on Loulo-Gounkoto Operations in Mali
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Barrick Gold Provides Update on Loulo-Gounkoto Operations in Mali
Jan 6, 2025 4:54 AM

07:33 AM EST, 01/06/2025 (MT Newswires) -- Barrick Gold ( GOLD ) on Monday said it remains restricted from shipping gold from its Loulo-Gounkoto mining complex in Mali.

The company said that an interim attachment order was issued against the existing gold stock on site which further prevents its export and disrupts normal operations. Barrick believes the interim attachment order is "unwarranted and is in contravention of the agreed dispute resolution mechanisms."

Barrick Chief Executive Mark Bristow said the inability to ship gold not only affects operations but has broader implications for the local economy, the 8,000 employees and its many local service providers.

"Barrick remains committed to constructive engagement with the Government of Mali to resolve the existing disputes amicably," said Bristow. "As previously disclosed, we have initiated arbitration through the International Centre for the Settlement of Investment Disputes (ICSID) as a recognized mechanism to address these matters of disagreement while maintaining the integrity of existing agreements. In parallel, Barrick continues its efforts to reach an agreement with the Mali government on a memorandum of agreement to resolve the existing disputes, redefine the partnership's future and increase the State's share of benefits from the Loulo-Gounkoto complex."

The company's U.S.-listed shares were last seen up 0.6% at $15.93 in pre-market trading. The shares traded on the Toronto Stock Exchange closed down $0.11, or 0.4%, at $22.9 on Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Darden Restaurants Insider Sold Shares Worth $489,895, According to a Recent SEC Filing
Darden Restaurants Insider Sold Shares Worth $489,895, According to a Recent SEC Filing
Oct 8, 2024
10:38 AM EDT, 10/08/2024 (MT Newswires) -- Melvin John Martin, President, SRG, on October 04, 2024, sold 3,000 shares in Darden Restaurants ( DRI ) for $489,895. Following the Form 4 filing with the SEC, Martin has control over a total of 12,601 shares of the company, with 12,601 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/940944/000122520824009221/xslF345X05/doc4.xml Price: 159.10, Change: -0.45, Percent...
Women-focused health startup Maven valued at $1.7 bln in funding round
Women-focused health startup Maven valued at $1.7 bln in funding round
Oct 8, 2024
* Maven raises $125 mln in funding round * Funding round led by investment firm StepStone * Maven's total funding climbs over $425 mln (Adds valuation in headline and paragraph 1, CEO comments in paragraphs 5-6) By Arasu Kannagi Basil and Niket Nishant Oct 8 (Reuters) - Women-focused healthcare firm Maven Clinic was valued at $1.7 billion after it raised...
Rogers to Launch Warner Bros. Discovery Brands in 2025
Rogers to Launch Warner Bros. Discovery Brands in 2025
Oct 8, 2024
10:37 AM EDT, 10/08/2024 (MT Newswires) -- Rogers Communications (RCI-B.TO) confirmed Tuesday that it will host the Warner Bros. Discovery's suite of English-language U.S. lifestyle and factual brands starting January 1, 2025. This follows Bell's (BCE.TO) decision to abandon its legal efforts to block Canadians from seeing Discovery channels, the Rogers statement noted. Rogers will launch TV channels for Discovery...
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates
Oct 8, 2024
On Monday, Vincerx Pharma ( VINC ) shared updates on its ongoing Phase 1 studies of VIP943, VIP236, and enitociclib, which aim to address various blood cancers. The ongoing Phase 1 dose-escalation study of VIP943 has enrolled 22 patients across several escalating dose cohorts (0.2 to 1.3 mg/kg once weekly). One patient with relapsed acute myeloid leukemia (AML) achieved complete...
Copyright 2023-2026 - www.financetom.com All Rights Reserved